Leerink Swan | GenomeWeb

Leerink Swan

To make up for the "lumpiness" of the market for genome-wide association studies, Affy will focus on applications that are downstream from GWAS, particularly in validation and routine testing, according to President and CEO Kevin King, who also shed some light on Affy's recent decision to sell its Clinical Services Laboratory to Navigenics.

NEJM last week published a quartet of perspectives offering a range of opinions on the value of GWAS and DTC testing, but two critical articles in particular caused financial analysts and the American news media to conclude that the perspectives could negatively impact companies that provide tools for these studies.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.